A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
Alcohol use disorder can make it difficult to control your drinking, which can harm your health and wellbeing. This Phase 3 clinical trial is testing a new medicine called brenipatide to see if it can help people safely reduce or stop drinking alcohol. Participants will be given either brenipatide or a placebo (a dummy treatment with no active medicine). The trial is open to adults aged 18 to 75 who are motivated to change their drinking habits. Taking part lasts around 56 weeks (just over a year). You will learn how to give yourself the medicine via an injection under the skin at home, keep a daily drinking diary, and attend regular check-ups at a study clinic. A team of healthcare professionals will monitor your health and safety throughout the trial.
At a glance
What is this study about?
Alcohol use disorder is a medical condition where someone finds it hard to control how much they drink, even when it causes problems in their life, relationships, or health. While there are existing support services and medications, they do not work for everyone. Researchers are actively looking for new treatments that can reduce cravings and help people regain control over their alcohol intake.
This Phase 3 study focuses on an investigational medicine called brenipatide. The main goal is to find out whether brenipatide is safe and effective in helping people with moderate-to-severe alcohol problems drink less or stop drinking completely. To ensure the results are trustworthy, the drug is being compared against a placebo, which looks identical but contains no active ingredients.
Participants will be placed into one of two groups by chance: one group receives brenipatide and the other receives the placebo. The medicine is taken as an injection just under the skin. Over the course of approximately 56 weeks, the study team will track participants' drinking habits, physical health, and general wellbeing.
Phase 3 trials are among the final stages of testing before a new medicine can be approved for general use. If brenipatide proves successful, it could offer a valuable new treatment option for people living with alcohol dependence in the UK and around the world.
Key takeaways
- Testing a new injectable medicine (brenipatide) for moderate-to-severe alcohol use disorder.
- Compares the study drug to an inactive dummy treatment (placebo) over 56 weeks.
- Open to adults aged 18 to 75 who are motivated to reduce or stop their alcohol intake.
- Requires participants to self-inject at home, keep a drinking diary, and attend clinic visits.
- Participation is completely voluntary, and you can withdraw at any time.
Who may be eligible?
This study is designed for adults aged 18 to 75 who have moderate-to-severe alcohol use disorder and genuinely want to cut down or quit drinking. To take part, you must be willing to attend regular clinic appointments, keep a study diary, fill in questionnaires, and learn how to give yourself injections at home.
For safety reasons, some people cannot join. You will not be able to take part if you have had problems with other illegal or non-prescribed substances in the last six months (nicotine and caffeine are allowed). People with advanced liver disease, such as cirrhosis or severe liver scarring, are also excluded, as are those who have recently had alcohol-related liver inflammation (hepatitis).
Additionally, the study is not suitable for individuals who have experienced serious thoughts of suicide or self-harm within the past six months, or for anyone who has taken part in another clinical drug trial within the last three months.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you between 18 and 75 years old?
- Do you want to cut down or completely stop drinking alcohol?
- Are you comfortable learning to give yourself injections under the skin?
- Are you free from serious liver problems such as cirrhosis?
- Have you been free from drug dependence (other than nicotine or caffeine) for at least 6 months?
- Are you able to attend regular clinic visits over a 56-week period?
What does participation involve?
If you take part, your involvement will last around 56 weeks (just over a year). You will need to attend regular appointments at a study clinic where a medical team will monitor your physical health through blood tests, blood pressure checks, and routine examinations. You will be trained to safely store the study medicine and inject it under your skin at home. You will also be asked to keep a regular diary of your alcohol use—using an app or a paper booklet—and answer questions about your mood and wellbeing. A dedicated clinical team will be available to support you throughout the trial.
Potential risks and benefits
Locations (117)
- Parkway Medical CenterVerified postcodeBirmingham, United States· Completed
- Headlands Research - ScottsdaleVerified postcodeScottsdale, United States· Active not recruiting
- Woodland International Research GroupVerified postcodeLittle Rock, United States· Completed
- UCLA Clinical & Translational Research Center (CTRC)Verified postcodeLos Angeles, United States· Active not recruiting
- Artemis Institute for Clinical ResearchVerified postcodeSan Diego, United States· Active not recruiting
- UCSF Weill Institute for Neurosciences - Substance Use Disorders Clinic - Mission BayVerified postcodeSan Francisco, United States· Active not recruiting
- Mountain Mind - DenverVerified postcodeDenver, United States· Active not recruiting
- Accel Research Sites - Lakeland Clinical Research UnitVerified postcodeLakeland, United States· Active not recruiting
- K2 Medical Research - MaitlandVerified postcodeMaitland, United States· Active not recruiting
- K2 Medical Research ORLANDOVerified postcodeMaitland, United States· Active not recruiting
- Life Arc Research Centers - MiamiVerified postcodeMiami, United States· Active not recruiting
- Wellness Research CenterVerified postcodeMiami, United States· Active not recruiting
Common questions
What is a placebo?
A placebo looks and feels identical to the real medicine but contains no active drug. It helps researchers prove whether any improvements are truly caused by the new treatment.
Will I know if I am getting brenipatide or the placebo?
No. Neither you nor the study doctors will know which treatment you are receiving until the study is finished. This 'blinded' approach helps keep the results fair and unbiased.
How do I take the medicine?
The medicine comes as an injection that goes just under the skin (subcutaneous). The clinical team will show you exactly how to do this safely at home.
Does it cost anything to take part?
No, the study medicine, visits, and tests are provided completely free of charge. You may also receive help with travel expenses to and from the clinic.
What if I decide I want to stop taking part?
You can leave the study at any point. Your decision will be fully respected, and you will continue to receive your usual medical care from your GP or NHS team.
How to find out more
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.